Medical Management to Treat Chronic Non-healing Ulcers: A Case Series

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Jan 3

PMID 38169779

Authors

Joseph Jose

Bhanushree Soni

Saji Jose

Jose K Kokkatt

Affiliations

Soon will be listed here.

Abstract

Introduction: Chronic non-healing leg ulcers are skin defects below the knee that resist healing for more than six weeks. They cause physical, emotional, and economic burdens to patients and society.

Objectives: To introduce an innovative medical strategy that targets the chronic inflammation component in non-healing ulcers (NHUs) with rheumatic features and to evaluate its potential effectiveness in achieving complete healing.

Methods: We employed an empirical medical therapy regimen, which combined medications like deflazacort, colchicine, dapsone, hydroxychloroquine, and azathioprine. We retrospectively selected 25 patients with chronic pedal ulcers who underwent our therapy.

Results: The mean duration of ulcers was 7.84 years, and the time to heal was 5.97 months. Among 25 patients, 19 had atypical ulcers, four had venous ulcers, and two had diabetic neuropathy ulcers. Four patients with venous ulcers additionally underwent endovenous laser ablation.

Conclusion: Our medical strategy showed promising results in healing chronic NHUs with rheumatic features without significant steroid-induced adverse effects.

References

Thomas D . Prevention and treatment of pressure ulcers. J Am Med Dir Assoc. 2006; 7(1):46-59. DOI: 10.1016/j.jamda.2005.10.004. View

Shukla V, Ansari M, Gupta S . Wound healing research: a perspective from India. Int J Low Extrem Wounds. 2005; 4(1):7-8. DOI: 10.1177/1534734604273660. View

Shanmugam V, Angra D, Rahimi H, McNish S . Vasculitic and autoimmune wounds. J Vasc Surg Venous Lymphat Disord. 2017; 5(2):280-292. PMC: 5319730. DOI: 10.1016/j.jvsv.2016.09.006. View

Pichler M, Thuile T, Gatscher B, Tappeiner L, DeLuca J, Larcher L . Systematic review of surgical treatment of pyoderma gangrenosum with negative pressure wound therapy or skin grafting. J Eur Acad Dermatol Venereol. 2016; 31(2):e61-e67. DOI: 10.1111/jdv.13727. View

Chu C, Chen Y, Lin M, Wu W, Liu F, Chen H . Association between Clinical Use of Colchicine and Risk of Type 2 Diabetes Mellitus among Gouty Patients: A Nationwide Cohort Study. Int J Environ Res Public Health. 2022; 19(6). PMC: 8955765. DOI: 10.3390/ijerph19063395. View

Suthar M, Gupta S, Bukhari S, Ponemone V . Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series. J Biomed Sci. 2017; 24(1):16. PMC: 5327512. DOI: 10.1186/s12929-017-0324-1. View

Hasselmann D, Bens G, Tilgen W, Reichrath J . Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges. 2007; 5(7):560-4. DOI: 10.1111/j.1610-0387.2007.0328.x. View

Probst S, Weller C, Bobbink P, Saini C, Pugliese M, Skinner M . Prevalence and incidence of venous leg ulcers-a protocol for a systematic review. Syst Rev. 2021; 10(1):148. PMC: 8117489. DOI: 10.1186/s13643-021-01697-3. View

Nayak S, Acharjya B . Deflazacort versus other glucocorticoids: a comparison. Indian J Dermatol. 2009; 53(4):167-70. PMC: 2763756. DOI: 10.4103/0019-5154.44786. View

10.

Micheletti R . Treatment of cutaneous vasculitis. Front Med (Lausanne). 2022; 9:1059612. PMC: 9716566. DOI: 10.3389/fmed.2022.1059612. View

11.

Seelig E, Meyer S, Timper K, Nigro N, Bally M, Pernicova I . Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol. 2017; 176(3):349-358. DOI: 10.1530/EJE-16-0653. View

12.

Monika P, Chandraprabha M, Rangarajan A, Waiker P, Murthy K . Challenges in Healing Wound: Role of Complementary and Alternative Medicine. Front Nutr. 2022; 8:791899. PMC: 8811258. DOI: 10.3389/fnut.2021.791899. View

13.

Zhao R, Liang H, Clarke E, Jackson C, Xue M . Inflammation in Chronic Wounds. Int J Mol Sci. 2016; 17(12). PMC: 5187885. DOI: 10.3390/ijms17122085. View

14.

Luhder F, Reichardt H . Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit Rev Immunol. 2009; 29(3):255-73. DOI: 10.1615/critrevimmunol.v29.i3.50. View

15.

Ronchetti S, Ayroldi E, Ricci E, Gentili M, Migliorati G, Riccardi C . A Glance at the Use of Glucocorticoids in Rare Inflammatory and Autoimmune Diseases: Still an Indispensable Pharmacological Tool?. Front Immunol. 2021; 11:613435. PMC: 7874096. DOI: 10.3389/fimmu.2020.613435. View

16.

Neeck G, Renkawitz R, Eggert M . Molecular aspects of glucocorticoid hormone action in rheumatoid arthritis. Cytokines Cell Mol Ther. 2003; 7(2):61-9. DOI: 10.1080/13684730412331302081. View

17.

Dastoli S, Nistico S, Morrone P, Patruno C, Leo A, Citraro R . Colchicine in Managing Skin Conditions: A Systematic Review. Pharmaceutics. 2022; 14(2). PMC: 8878049. DOI: 10.3390/pharmaceutics14020294. View

18.

Eming S, Krieg T, Davidson J . Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007; 127(3):514-25. DOI: 10.1038/sj.jid.5700701. View

19.

Tsachiridi M, Galyfos G, Andreou A, Sianou A, Sigala F, Zografos G . Autologous Platelet-Rich Plasma for Nonhealing Ulcers: A Comparative Study. Vasc Specialist Int. 2019; 35(1):22-27. PMC: 6453601. DOI: 10.5758/vsi.2019.35.1.22. View

20.

Avishai E, Yeghiazaryan K, Golubnitschaja O . Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J. 2017; 8(1):23-33. PMC: 5471802. DOI: 10.1007/s13167-017-0081-y. View